Search
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigational[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels. … [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653]
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesProducts: XCOPRI TITRATION PACK 50 mg, 100 mg, XCOPRI TITRATION PACK 12.5 mg, 25 mgDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexProducts: Vizimpro 15 mg Film-Coated Tablets, VİZİMPRO 15 MG FİLM KAPLI TABLET, 30 ADETRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalFood and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. … Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S.
Categories: Heterocyclic Compounds, 1-Ring, Antivirals used in combination for the treatment of HIV infectionsProducts: ISENTRESS® TABLETAS MASTICABLES 25 MG, ISENTRESS® GRÁNULOS PARA SUSPENSIÓN ORAL 100 MGBesifloxacin
go.drugbank.com/drugs/DB06771ApprovedBesifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Categories: Heterocyclic Compounds, 1-Ring, 4-QuinolonesProducts: BESIVANCE % 0,6 OFTALMIK SÜSPANSIYON, 5 MLIodide I-131
go.drugbank.com/drugs/DB09293ApprovedInvestigationalIodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. … Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy.
Synonyms: 131 I, 131-ISalts: Sodium iodide I-131Intermedine
go.drugbank.com/drugs/DB17612InvestigationalSynonyms: N-acetyl-acth(1-13)-amide, Valinamide, acetyl-l-seryl-l-tyrosyl-l-seryl-l-methionyl-l-glutamyl-l-histidyl-l-phenylalanyl-l-arginyl-l-tryptophyl-glycyl-l-lysyl-l-prolyl-, l-Categories: Heterocyclic Compounds, 2-RingBezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalIt decreases low density lipoproteins and increases high density lipoproteins.
Synonyms: 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acidCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsFludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigational[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position … Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: FLOCURTIN® 0.1 MG TABLETAS, ASTONIN-H 0,1 MG TABLET, 100 ADETManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedManganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Synonyms: Manganese D-gluconateMixtures: Vitamin E 400 Iu With Selenium, Vitamin C & Manganese, Cal-mag Plus K, Mn and Zn CapletsPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MG